119 related articles for article (PubMed ID: 23480583)
1. Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond.
Ensinger C
Expert Opin Med Diagn; 2011 Mar; 5(2):91-4. PubMed ID: 23480583
[TBL] [Abstract][Full Text] [Related]
2. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
3. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
5. DxS Ltd.
Cross J
Pharmacogenomics; 2008 Apr; 9(4):463-7. PubMed ID: 18384259
[TBL] [Abstract][Full Text] [Related]
6. Do companion diagnostics make economic sense for drug developers?
Agarwal A
N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
[TBL] [Abstract][Full Text] [Related]
7. Improving the power of diagnostics in the era of targeted therapy and personalized healthcare.
Walk EE
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):226-34. PubMed ID: 20205056
[TBL] [Abstract][Full Text] [Related]
8. Advances in treatment of lung cancer with targeted therapy.
Cagle PT; Chirieac LR
Arch Pathol Lab Med; 2012 May; 136(5):504-9. PubMed ID: 22540298
[TBL] [Abstract][Full Text] [Related]
9. Molecular tools for companion diagnostics.
Zieba A; Grannas K; Söderberg O; Gullberg M; Nilsson M; Landegren U
N Biotechnol; 2012 Sep; 29(6):634-40. PubMed ID: 22634023
[TBL] [Abstract][Full Text] [Related]
10. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
Philip R; Carrington L; Chan M
Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
[TBL] [Abstract][Full Text] [Related]
11. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
12. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Ozols RF; Herbst RS; Colson YL; Gralow J; Bonner J; Curran WJ; Eisenberg BL; Ganz PA; Kramer BS; Kris MG; Markman M; Mayer RJ; Raghavan D; Reaman GH; Sawaya R; Schilsky RL; Schuchter LM; Sweetenham JW; Vahdat LT; Winn RJ;
J Clin Oncol; 2007 Jan; 25(1):146-62. PubMed ID: 17158528
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
Parkinson DR; Johnson BE; Sledge GW
Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
[TBL] [Abstract][Full Text] [Related]
15. Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer.
Plönes T; Engel-Riedel W; Stoelben E; Limmroth C; Schildgen O; Schildgen V
J Pers Med; 2016 Jan; 6(1):. PubMed ID: 26784235
[TBL] [Abstract][Full Text] [Related]
16. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies.
Papadopoulos N; Kinzler KW; Vogelstein B
Nat Biotechnol; 2006 Aug; 24(8):985-95. PubMed ID: 16900147
[TBL] [Abstract][Full Text] [Related]
17. Recent developments and future perspectives of personalized oncology.
Grüllich C; von Kalle C
Onkologie; 2012; 35 Suppl 1():4-7. PubMed ID: 22286581
[TBL] [Abstract][Full Text] [Related]
18. Drug development for cancer chemoprevention: focus on molecular targets.
Johnson KA; Brown PH
Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
[TBL] [Abstract][Full Text] [Related]
19. Using companion and coupled diagnostics within strategy to personalize targeted medicines.
Singer DR; Watkins J
Per Med; 2012 Sep; 9(7):751-761. PubMed ID: 29776269
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer in the 21st century: neu opportunities and neu challenges.
Schnitt SJ
Mod Pathol; 2001 Mar; 14(3):213-8. PubMed ID: 11266529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
